Role of collagenase clostridium histolyticum in Peyronie’s disease
Peyronie’s disease is a localized connective tissue disease characterized by an active, inflammatory phase and a stable, quiescent phase, with the eventual development of collagenous plaques within the tunica albuginea of the penis. Risk factors primarily associated with Peyronie’s disease include D...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598203/ https://www.ncbi.nlm.nih.gov/pubmed/26491251 http://dx.doi.org/10.2147/BTT.S65619 |
_version_ | 1782394052224745472 |
---|---|
author | Peak, Taylor C Mitchell, Gregory C Yafi, Faysal A Hellstrom, Wayne J |
author_facet | Peak, Taylor C Mitchell, Gregory C Yafi, Faysal A Hellstrom, Wayne J |
author_sort | Peak, Taylor C |
collection | PubMed |
description | Peyronie’s disease is a localized connective tissue disease characterized by an active, inflammatory phase and a stable, quiescent phase, with the eventual development of collagenous plaques within the tunica albuginea of the penis. Risk factors primarily associated with Peyronie’s disease include Dupuytren’s contracture, penile trauma, and family history. A variety of treatment strategies have been utilized, including oral and topical agents, electromotive drug administration, intralesional injections, extracorporeal shockwave therapy, penile traction, and surgery. However, most of these strategies are ineffective, with surgery being the only definitive treatment. Collagenase clostridium histolyticum is a newly US Food and Drug Administration-approved agent for intralesional injection. It is thought to downregulate many of the disease-related genes, cytokines, and growth factors and degrade collagen fibers. It also suppresses cell attachment, spreading, and proliferation. Collagenase clostridium histolyticum has been clinically proven to be a safe and effective therapeutic option, demonstrating decreases in penile curvature and plaque consistency, as well as increases in patient satisfaction. During clinical evaluation, the Peyronie’s Disease Questionnaire was validated as an effective tool for assessing treatment outcomes. |
format | Online Article Text |
id | pubmed-4598203 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45982032015-10-21 Role of collagenase clostridium histolyticum in Peyronie’s disease Peak, Taylor C Mitchell, Gregory C Yafi, Faysal A Hellstrom, Wayne J Biologics Review Peyronie’s disease is a localized connective tissue disease characterized by an active, inflammatory phase and a stable, quiescent phase, with the eventual development of collagenous plaques within the tunica albuginea of the penis. Risk factors primarily associated with Peyronie’s disease include Dupuytren’s contracture, penile trauma, and family history. A variety of treatment strategies have been utilized, including oral and topical agents, electromotive drug administration, intralesional injections, extracorporeal shockwave therapy, penile traction, and surgery. However, most of these strategies are ineffective, with surgery being the only definitive treatment. Collagenase clostridium histolyticum is a newly US Food and Drug Administration-approved agent for intralesional injection. It is thought to downregulate many of the disease-related genes, cytokines, and growth factors and degrade collagen fibers. It also suppresses cell attachment, spreading, and proliferation. Collagenase clostridium histolyticum has been clinically proven to be a safe and effective therapeutic option, demonstrating decreases in penile curvature and plaque consistency, as well as increases in patient satisfaction. During clinical evaluation, the Peyronie’s Disease Questionnaire was validated as an effective tool for assessing treatment outcomes. Dove Medical Press 2015-09-29 /pmc/articles/PMC4598203/ /pubmed/26491251 http://dx.doi.org/10.2147/BTT.S65619 Text en © 2015 Peak et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Peak, Taylor C Mitchell, Gregory C Yafi, Faysal A Hellstrom, Wayne J Role of collagenase clostridium histolyticum in Peyronie’s disease |
title | Role of collagenase clostridium histolyticum in Peyronie’s disease |
title_full | Role of collagenase clostridium histolyticum in Peyronie’s disease |
title_fullStr | Role of collagenase clostridium histolyticum in Peyronie’s disease |
title_full_unstemmed | Role of collagenase clostridium histolyticum in Peyronie’s disease |
title_short | Role of collagenase clostridium histolyticum in Peyronie’s disease |
title_sort | role of collagenase clostridium histolyticum in peyronie’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598203/ https://www.ncbi.nlm.nih.gov/pubmed/26491251 http://dx.doi.org/10.2147/BTT.S65619 |
work_keys_str_mv | AT peaktaylorc roleofcollagenaseclostridiumhistolyticuminpeyroniesdisease AT mitchellgregoryc roleofcollagenaseclostridiumhistolyticuminpeyroniesdisease AT yafifaysala roleofcollagenaseclostridiumhistolyticuminpeyroniesdisease AT hellstromwaynej roleofcollagenaseclostridiumhistolyticuminpeyroniesdisease |